6 Sep 2017 13:41
EKF Diagnostics Holdings plc
("EKF", the "Company")
Reduction of capital
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, announces that the reduction of the Company's share capital necessary in order for the Company to proceed with its share buyback plan of up to 15% of the Company's current issued share capital has now been approved by the court.
Details of the reduction of capital were set out in the circular to shareholders dated 26 June 2017 and the proposal was approved by shareholders at the General Meeting held on 27 July 2017.
The Company is currently in a close period ahead of the publication of its interim results on 11 September 2017 and further announcements will be made in connection with the commencement of the share buyback at the appropriate time.
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
Christopher Mills, Non-Executive Chairman | Tel: 029 2071 0570 |
Julian Baines, CEO | |
Richard Evans, FD & COO | |
N+1 Singer (Nomad & Broker) | Tel: 020 7496 3000 |
Alex Price / Shaun Dobson / Ali Laughton-Scott | |
Walbrook PR Limited | Tel: 020 7933 8780 or ekf@walbrookpr.com |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 |
Ekf Diagnostics (EKF)